Dysfunctional Myelopoiesis and Myeloid-Derived Suppressor Cells in Sepsis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-100
SponsorUniversity of Florida
About this trial
Adverse outcomes in surgical sepsis patients are secondary to dysregulated emergency myelopoiesis, and expansion of myeloid-derived suppressor cells. Here we propose to determine the underlying mechanisms behind the increased expansion of these leukocyte populations and the underlying mechanisms that drive inflammation and immune suppression.
Eligibility criteria
Qualifiers
age ≥18 years
meets criteria for sepsis/septic shock by Sepsis-3 consensus criteria.
Disqualifiers
have disease states that predispose to significant immune system dysfunction
known pregnancy
enrollment >96 hours after suspected sepsis onset
pre-hospitalization bedridden performance status (WHO/Zubrod score ≥4)
Trial design
Treatments tested in this trial
- Blood sampling
Treatment groups
450 Participants
are divided into 3 treatment groupsSponsors and collaborators
University of Florida
Lead sponsor
National Institute of General Medical Sciences (NIGMS)
Collaborator
Source ClinicalTrials.gov